¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼ : Ä¡·á¹ýº°, µ¿¹°º°, ¾Ï À¯Çüº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
U.S. Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy (Surgery, Radiology, Chemotherapy, Immunotherapy), By Animal (Canine, Feline), By Cancer Type (Skin Cancer, Lymphoma, Sarcomas), And Segment Forecasts, 2024 - 2030
»óǰÄÚµå
:
1552573
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 08¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 150 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå ±Ô¸ð´Â 2024-2030³â°£ 10.76%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³»°í, 2030³â±îÁö 10¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹Ý·Áµ¿¹°ÀÇ ¾Ï À¯º´·ü Áõ°¡, ¹Ý·Áµ¿¹° ¼ÒÀ¯ÁÖµéÀÇ ¹Ý·Áµ¿¹°À» À§ÇÑ ÁöÃâ ÀÇÇâ, ¿¬±¸ÀÚµéÀÌ ÀÓ»ó½ÃÇè ¸ðµ¨·Î °³¸¦ »ç¿ëÇÏ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, °í¾çÀÌÀÇ ¾Ï ¹ßº´·ü Áõ°¡¿Í ¹Ý·Áµ¿¹°ÀÇ °Ç°¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇÑ ¹Ý·Áµ¿¹° »çÀ°·ü Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ±â¾÷µéÀº ½ÃÀå¿¡¼ÀÇ ÀÔÁö¸¦ °ÈÇϱâ À§ÇØ ÀμöÇÕº´, ¿¬±¸ °è¾à, Á¦ÈÞ, ÆÄÆ®³Ê½Ê, Áö¸®Àû È®Àå, Á¦Ç° °³¹ß µîÀÇ Àü·«À» äÅÃÇÏ´Â °æÇâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, 2020³â 11¿ù ¹ö¹Ú(Virbac)Àº °³ ºñ¸¸¼¼Æ÷Á¾¿¡ ´ëÇÑ »õ·Î¿î Á¾¾ç ³» ÁÖ»ç Ä¡·áÁ¦ÀÎ ½ºÅÚÆùŸ(Stelfonta)ÀÇ ½ÂÀÎÀ» ¹ßÇ¥Çß½À´Ï´Ù. ¶ÇÇÑ Elanco´Â ¹Ý·Áµ¿¹° ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀ» À§ÇØ Aratana Therapeutics¸¦ ÀμöÇß½À´Ï´Ù. ÀÌ È¸»ç´Â ¶ÇÇÑ VetDC·ÎºÎÅÍ ¶ó¹ÙÄíÆ÷»çµò(Tanovea)À» °³¹ßÇϱâ À§ÇÑ °è¾àÀ» ü°áÇß½À´Ï´Ù. ¶ÇÇÑ 2021³â 7¿ù ¿¤¶ûÄÚ´Â FDA°¡ °³ ¸²ÇÁÁ¾ Ä¡·áÁ¦·Î¼ Ÿ³ëº£¾Æ¿¡ ´ëÇÑ ¿ÏÀüÇÑ ½ÂÀÎÀ» ¹Þ¾Ò´Ù°í ¼±¾ðÇß½À´Ï´Ù. µû¶ó¼ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È Ä¡¿ÇÑ °æÀïÀ» È®ÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ý·Áµ¿¹°ÀÇ ¾Ï À¯º´·ü Áõ°¡´Â È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀÇ Çʿ伺À» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°³¿¡¼ ¸ÍÀå°ñÀ°Á¾Àº ¸Å¿ì °ø°ÝÀûÀÎ ÁúȯÀ¸·Î, ¿ÏÄ¡¸¦ À§ÇÑ Ä¡·á´Â Á¾¾çÀÇ ¿Ü°úÀû ÀýÁ¦¼ú°ú Á¾¾ç ¼¼Æ÷°¡ ´Ù¸¥ ºÎÀ§, ƯÈ÷ Æó·Î ÀüÀÌµÉ À§ÇèÀ» ÁÙÀ̱â À§ÇÑ ÈÇпä¹ýÀ¸·Î ÀÌ·ç¾îÁý´Ï´Ù. °ñµç ¸®Æ®¸®¹ö¶ó´Â °ßÁ¾Àº ´Ù¸¥ °ßÁ¾¿¡ ºñÇØ ¾Ï ¹ßº´·üÀÌ ³ôÀº °ÍÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù. °ñµç ¸®Æ®¸®¹ö´Â ¹Ì±¹¿¡¼ °¡Àå Àαâ ÀÖ´Â °ßÁ¾ Áß ÇϳªÀ̸ç, ¹Ý·Áµ¿¹°ÀÇ °Ç°¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇèÀº ¼öÀÇ Á¾¾çÇп¡¼ Áß¿äÇÑ ºÎºÐÀÔ´Ï´Ù. ¹Ý·Áµ¿¹° ¼ö¼úÀ» Æ÷ÇÔÇÑ ÀÓ»ó ¿¬±¸ÀÇ °¡¼ÓÈ´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, 2019³â 5¿ù ¿À¸®°Ç ÁÖ¸³´ëÇÐÀº Á¾¾çÀ» ¿ÏÀüÈ÷ Á¦°ÅÇÑ °³¿¡¼ ¾Ï Àç¹ß À§ÇèÀÌ 60%±îÁö °¨¼ÒÇß´Ù´Â ¿¬±¸ °á°ú¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ¹Ì±¹¿¡¼´Â ¹Ý·Áµ¿¹°À» Ű¿ì´Â Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó µ¿¹° °Ç°¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼´Â Àü±¹ ¹Ý·Áµ¿¹° ÁÖ°£ µî ¹Ý·Áµ¿¹° °Ç°¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ ´Ù¾çÇÑ Çà»ç°¡ ¿¸®°í ÀÖ½À´Ï´Ù. µ¿¹°ÀÌ °³Àο¡°Ô Äڷγª19¸¦ Àü¿°½Ãų À§ÇèÀº °ÅÀÇ ¾ø´Â °ÍÀ¸·Î ¿©°ÜÁöÁö¸¸, FDA´Â Äڷγª19ÀÇ ´ëÀ¯ÇàÀÌ µ¿¹°¿ë ½Å¾à °³¹ßÀ» À§ÇÑ ÁøÇà ÁßÀÎ ¿¬±¸¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Ù°í °æ°íÇß½À´Ï´Ù. ÀÌ¿¡ µû¶ó 2020³â 4¿ù, Äڷγª19°¡ µ¿¹° ½Å¾à °³¹ß¿¡ ¹ÌÄ¥ ¼ö ÀÖ´Â ÀáÀçÀû ¿µÇâÀ» ÁÙÀ̱â À§ÇÑ °¡À̵å¶óÀÎÀ» ¹ßÇ¥Çß½À´Ï´Ù.
¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ¹æ»ç¼±ÇÐ ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »õ·Î¿î µ¿¹°¿ë ¹æ»ç¼± ¼¾ÅÍ ¼³¸³À» À§ÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡¿Í ¹æ»ç¼± ±â¼úÀÇ ¹ßÀü°ú °°Àº ¿äÀÎÀÌ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ¸é¿ªÄ¡·á ºÎ¹®Àº ¸é¿ªÄ¡·á ºÎ¹®ÀÇ ÀÓ»ó½ÃÇè¿¡ ÁýÁßÇÏ´Â µ¿¹°º´¿øÀÌ Áõ°¡ÇÔ¿¡ µû¶ó 2023-2030³â »çÀÌ °¡Àå ºü¸¥ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
- Cancer Veterinary Center¿¡ µû¸£¸é ÈÇпä¹ýÀº 2030³â±îÁö µÎ ¹øÂ°·Î Å« Ä¡·á ºÎ¹®ÀÌ µÉ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ÈÇпä¹ýÀ¸·Î Ä¡·áÇÏ´Â °¡Àå ÈçÇÑ °³¿Í °í¾çÀÌ Á¾¾çÀº °ñÀ°Á¾, ¸²ÇÁÁ¾, Ç÷°üÀ°Á¾, ºñ¸¸¼¼Æ÷Á¾, ¹æ±¤Á¾¾ç, À¯¼±Á¾¾ç µîÀÔ´Ï´Ù.
- °³ ºÎ¹®Àº 2023³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¹Ý·Á°ßÀÇ ³ôÀº ¾Ï ¹ßº´·ü°ú ÀÌ ºÐ¾ß¿¡¼ ÁøÇà ÁßÀÎ Á¦Ç° Çõ½ÅÀÌ ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©Çß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ½ÃÀå ±âȸ ºÐ¼®
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦ ºÐ¼®
- ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå ºÐ¼® Åø
- PorterÀÇ Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19 ºÐ¼®
- ÁÖ¿ä ±¹°¡º° ÃßÁ¤ Æê Àα¸
Á¦4Àå ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå : µ¿¹°, ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀ庯¼ö ºÐ¼®
- ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, µ¿¹°º°, 2018-2030³â
- °³
- °í¾çÀÌ
- ¸»
Á¦5Àå ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå : Ä¡·á¹ý, ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀ庯¼ö ºÐ¼®
- ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Ä¡·á¹ýº°, 2018-2030³â
- ¹æ»ç¼± Ä¡·á
- ¼ö¼ú
- ÈÇпä¹ý
- ¸é¿ªÄ¡·á
- ±âŸ
Á¦6Àå ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå : ¾Ï À¯Çü, ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀ庯¼ö ºÐ¼®
- ¹Ì±¹ÀÇ ¼öÀÇ Á¾¾çÇÐ ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¾Ï À¯Çüº°, 2018-2030³â
- ÇǺξÏ
- ¸²ÇÁÁ¾
- À°Á¾
- ±âŸ
Á¦7Àå °æÀï ±¸µµ
- ½ÃÀå ÁøÃâ±â¾÷ ºÐ·ù
- ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®/È÷Æ®¸Ê ºÐ¼®
- 2023³â ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ÃßÁ¤ ºÐ¼®
- Àü·« ¸ÅÇÎ
- ÀμöÇÕº´(M&A)
- ÆÄÆ®³Ê½Ê°ú Çù¾÷
- ±âŸ
- ±â¾÷ °³¿ä
- Elanco
- Boehringer Ingelheim International GmbH.
- Zoetis
- PetCure Oncology
- Accuray Incorporated
- Varian Medical Systems, Inc.
- Elekta AB.
- Karyopharm Therapeutics, Inc.
- Virbac.
- Merck &Co., Inc.
- Dechra Pharmaceuticals PLC
- NovaVive Inc.
- Ardent Animal Health, LLC(A BreakthrU Company).
Á¦8Àå ÁÖ¿ä Æ÷ÀÎÆ®
LSH
¿µ¹® ¸ñÂ÷
U.S. Veterinary Oncology Market Growth & Trends:
The U.S. veterinary oncology market size is expected to reach USD 1.08 billion by 2030, registering a CAGR of 10.76% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canines as a model for clinical trials by researchers are the key contributing factor toward the market growth. In addition, a rise in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth. Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.
For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline. The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC. In addition, in July 2021, Elanco proclaimed that the FDA granted full approval of Tanovea for the lymphoma treatment in dogs. Hence, the market is expected to witness intense competition over the forecast period. The growing prevalence of cancer in companion animals is expected to propel the need for effective treatment options.
In canines, appendicular osteosarcoma is an extremely aggressive illness and curative-intent treatment comprises surgical resection of the tumor followed by chemotherapy to diminish the risk of tumor cells spreading to other areas, particularly the lungs. The golden retriever breed has been reported to have a high cancer prevalence compared to others. Golden Retriever is one of the favorite breeds in the U.S. and increasing concerns regarding the wellbeing of pets are contributing to the market growth. Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth.
For instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected. With the growing number of pet parents in the U.S., animal health awareness is rising among people. In the U.S., various pet health awareness events are conducted to spread awareness, such as National Pet Week. The risk of animals spreading COVID-19 to individuals is considered to be little. The FDA is alert that the COVID-19 pandemic may influence the ongoing studies being conducted to provision new animal drug development. Thereby, guidelines were issued in April 2020 to help diminish the potential impact of the pandemic on new animal drug development.
U.S. Veterinary Oncology Market Report Highlights:
- The radiology segment is expected to dominate the market. Factors, such as increasing government initiatives for the establishment of new veterinary radiation centers and advancements in radiation technology, are expected to boost the segment growth
- The immunotherapy segment is estimated to register the fastest CAGR from 2023 to 2030 owing to the growing number of veterinary centers focused on carrying out clinical trials in immunotherapy areas
- Chemotherapy is estimated to be the second-largest therapy segment by 2030. According to the Cancer Veterinary Center, the most common canine & feline tumors treated with chemotherapy are osteosarcomas, lymphomas, hemangiosarcoma, mast cell tumors, bladder tumors, mammary gland tumors, etc.
- The canine segment accounted for the largest revenue share in 2023. The high incidence of cancer in canines and ongoing product innovations in this domain contributed to the segment growth
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Scope
- 1.1.2. Estimates And Forecast Timeline
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis
- 1.6.2. Global Market: CAGR Calculation
- 1.7. Research Scope and Assumptions
- 1.7.1. List of Secondary Sources
- 1.7.2. List of Primary Sources
- 1.7.3. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Veterinary Oncology Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
- 3.2.1.1. Increasing Prevalence Of Cancer In Pets
- 3.2.1.2. Increasing R&D In Pet Cancer Therapy
- 3.2.1.3. Growing Focus On Animal Safety
- 3.2.1.4. Growing Uptake Of Pet Insurance
- 3.2.1.5. Technological Advancements In Pet Cancer Treatment
- 3.2.1.6. Increase In Pet Population
- 3.2.2. Market Restraints Analysis
- 3.2.2.1. High cost of treatment
- 3.2.2.2. Adverse effects associated with therapies
- 3.2.2.3. Limited Clinical Evidence
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenges Analysis
- 3.3. U.S. Veterinary Oncology Market Analysis Tools
- 3.3.1. Porter's Analysis
- 3.3.1.1. Bargaining power of the suppliers
- 3.3.1.2. Bargaining power of the buyers
- 3.3.1.3. Threats of substitution
- 3.3.1.4. Threats from new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and Social Landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Environmental Landscape
- 3.3.2.5. Legal landscape
- 3.4. Covid-19 Analysis
- 3.5. Estimated Pet Population, by key countries
Chapter 4. U.S. Veterinary Oncology Market: Animal Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. U.S. Veterinary Oncology Market Movement Analysis
- 4.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
- 4.4. Canine
- 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.5. Feline
- 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.6. Equine
- 4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Veterinary Oncology Market: Therapy Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. U.S. Veterinary Oncology Market Movement Analysis
- 5.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
- 5.4. Radiotherapy
- 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.2. Stereotactic Radiation Therapy
- 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.2.2. LINAC
- 5.4.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.2.3. Other Type
- 5.4.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.3. Conventional Radiation Therapy
- 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5. Surgery
- 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.6. Chemotherapy
- 5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.7. Immunotherapy
- 5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.8. Other Therapies
- 5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. U.S. Veterinary Oncology Market Movement Analysis
- 6.3. U.S. Veterinary Oncology Market Size & Trend Analysis, by Cancer Type, 2018 to 2030 (USD Million)
- 6.4. Skin Cancer
- 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5. Lymphomas
- 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6. Sarcomas
- 6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7. Others
- 6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Market Participant Categorization
- 7.2. Company Market Position Analysis/ Heat Map Analysis
- 7.3. Estimated Company Market Share Analysis, 2023
- 7.4. Strategy Mapping
- 7.4.1. Mergers & Acquisitions
- 7.4.2. Partnerships & Collaborations
- 7.4.3. Others
- 7.5. Company Profiles
- 7.5.1. Elanco
- 7.5.1.1. Participant's Overview
- 7.5.1.2. Financial Performance
- 7.5.1.3. Product Benchmarking
- 7.5.1.4. Strategic Initiatives
- 7.5.2. Boehringer Ingelheim International GmbH.
- 7.5.2.1. Participant's Overview
- 7.5.2.2. Financial Performance
- 7.5.2.3. Product Benchmarking
- 7.5.2.4. Strategic Initiatives
- 7.5.3. Zoetis
- 7.5.3.1. Participant's Overview
- 7.5.3.2. Financial Performance
- 7.5.3.3. Product Benchmarking
- 7.5.3.4. Strategic Initiatives
- 7.5.4. PetCure Oncology
- 7.5.4.1. Participant's Overview
- 7.5.4.2. Financial Performance
- 7.5.4.3. Product Benchmarking
- 7.5.4.4. Strategic Initiatives
- 7.5.5. Accuray Incorporated
- 7.5.5.1. Participant's Overview
- 7.5.5.2. Financial Performance
- 7.5.5.3. Product Benchmarking
- 7.5.5.4. Strategic Initiatives
- 7.5.6. Varian Medical Systems, Inc.
- 7.5.6.1. Participant's Overview
- 7.5.6.2. Financial Performance
- 7.5.6.3. Product Benchmarking
- 7.5.6.4. Strategic Initiatives
- 7.5.7. Elekta AB.
- 7.5.7.1. Participant's Overview
- 7.5.7.2. Financial Performance
- 7.5.7.3. Product Benchmarking
- 7.5.7.4. Strategic Initiatives
- 7.5.8. Karyopharm Therapeutics, Inc.
- 7.5.8.1. Participant's Overview
- 7.5.8.2. Financial Performance
- 7.5.8.3. Product Benchmarking
- 7.5.8.4. Strategic Initiatives
- 7.5.9. Virbac.
- 7.5.9.1. Participant's Overview
- 7.5.9.2. Financial Performance
- 7.5.9.3. Product Benchmarking
- 7.5.9.4. Strategic Initiatives
- 7.5.10. Merck & Co., Inc.
- 7.5.10.1. Participant's Overview
- 7.5.10.2. Financial Performance
- 7.5.10.3. Product Benchmarking
- 7.5.10.4. Strategic Initiatives
- 7.5.11. Dechra Pharmaceuticals PLC
- 7.5.11.1. Participant's Overview
- 7.5.11.2. Financial Performance
- 7.5.11.3. Product Benchmarking
- 7.5.11.4. Strategic Initiatives
- 7.5.12. NovaVive Inc.
- 7.5.12.1. Participant's Overview
- 7.5.12.2. Financial Performance
- 7.5.12.3. Product Benchmarking
- 7.5.12.4. Strategic Initiatives
- 7.5.13. Ardent Animal Health, LLC (A BreakthrU Company).
- 7.5.13.1. Participant's Overview
- 7.5.13.2. Financial Performance
- 7.5.13.3. Product Benchmarking
- 7.5.13.4. Strategic Initiatives
Chapter 8. Key Takeaways
°ü·ÃÀÚ·á